Herbs plus chemo and immunotherapy to prevent lung cancer spread
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether staged Chinese herbal medicine added to standard treatment can lower the risk of lung cancer coming back or spreading after surgery. It is for people with stage Ib to IIIb non-small cell lung cancer whose tests show no “driver gene” targets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer was fully removed by surgery with clear margins (R0) and is stage Ib to IIIb
- Your tumor testing (tissue or blood) shows no driver gene changes
- You started your first chemotherapy within 8 weeks after surgery
- You are age 18 to 74, can do usual daily activities (ECOG 0 to 2), and your blood counts are high enough
- Your liver and kidney tests are not abnormal, and you can understand and sign consent
- You are not pregnant or breastfeeding, and you do not have serious drug allergies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial is testing whether adding a traditional Chinese herbal formula (Modified Si Jun Zi Tang) to standard treatment before and after surgery can help people with early-stage non-small cell lung cancer. It aims to see if the herbs improve outcomes and reduce side effects.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This Phase 2 study looks at whether adding an immunotherapy medicine (camrelizumab) to standard chemotherapy after lung surgery can help prevent lung cancer from coming back. It is for people with stage IIA–IIIA non-small cell lung cancer who cannot use targeted (mutation-based) adjuvant therapy.
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.